OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 USD | +17.86% |
|
0.00% | +9.27% |
| 08/05 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| 17/04 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Weaknesses
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +9.27% | 6.8Cr | - | ||
| +10.49% | 895.73Cr | A- | ||
| -10.76% | 518.56Cr | A- | ||
| +51.58% | 476.76Cr | - | ||
| +12.50% | 426.22Cr | B- | ||
| -20.70% | 236.89Cr | C- | ||
| +13.08% | 229.5Cr | B | ||
| -29.65% | 220.86Cr | - | ||
| +19.51% | 217.28Cr | - | - | |
| -0.50% | 164.41Cr | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORX Stock
- ORXOY Stock
- Ratings Orexo AB
